Brief: Aridis Pharmaceuticals To Discuss Topline Data From Phase 3 Study Of Ar-301 On Call On January 25
28/12/2022 15:08
Dec 28 (Reuters) - Aridis Pharmaceuticals Inc ARDS.O :
* ARIDIS PHARMACEUTICALS TO DISCUSS TOPLINE DATA FROM PHASE
3
STUDY OF AR-301 DURING CORPORATE UPDATE CALL ON JANUARY 25
Source text for Eikon: ID:nGNXb90vwS
Further company coverage: ARDS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Aridis Pharmaceuticals
See all newsBrief: Aridis Pharmaceuticals Inc - On September 7 Nasdaq Announced That It Would Delist Common Stock Of Co
U.S. STOCKS ON THE MOVE-Pieris Pharma, Microsoft, Energy sector
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
U.S. STOCKS ON THE MOVE-Teladoc Health, NVDIA, Chipotle
U.S. STOCKS ON THE MOVE-Pinterest, Sunrun, Tencent Music